1. Introduction {#sec1-jcm-08-01550}
===============

Benign prostatic hyperplasia (BPH), which is a key cause of lower urinary tract symptoms (LUTS) in older men, affects approximately 210 million men worldwide \[[@B1-jcm-08-01550]\]. A study revealed that 50% of men developed pathological BPH at the age of 51--60 years \[[@B2-jcm-08-01550]\]. Moreover, BPH/LUTS prevalence is expected to increase sharply in the coming decades \[[@B3-jcm-08-01550]\]. The sequelae of BPH include decreased urinary flow and progression of voiding and storage symptoms, which eventually results in acute or chronic urinary retention (UR) \[[@B4-jcm-08-01550]\]. BPH with moderate-to-severe LUTS considerably affects all aspects of the quality of life of men as they age \[[@B5-jcm-08-01550]\]. A 50-year-old from the United States has an estimated risk of approximately 40% of undergoing therapeutic intervention (surgical or medical treatment) at some point during his lifetime \[[@B6-jcm-08-01550]\]. Accordingly, billions of US dollars are spent annually to treat BPH/LUTS \[[@B7-jcm-08-01550]\].

Both alpha-1 blockers and transurethral resection of the prostate (TURP) achieve favorable treatment outcomes in most patients with benign prostatic obstruction (BPO) \[[@B8-jcm-08-01550]\]. Alpha-1 blockers are used for first-line treatment of BPO in men with LUTS \[[@B9-jcm-08-01550]\]. In patients with unsatisfactory response to medication, TURP remains the dominant and definitive treatment for LUTS caused by BPH \[[@B10-jcm-08-01550]\]. Some studies have also reported that TURP achieves favorable outcomes even for BPH patients with comorbidities such as UR, type 2 diabetes, and stroke \[[@B11-jcm-08-01550],[@B12-jcm-08-01550],[@B13-jcm-08-01550]\]. Nevertheless, to the best of our knowledge, no studies have addressed the long-term sequelae for patients with "unfavorable" outcomes from either medical or surgical treatment. Therefore, we used Taiwan National Health Insurance Research Database (NHIRD) data to conduct a nationwide observational cohort study for investigating the correlation between the treatment outcomes of BPH/LUTS and lifelong health status, including urologic cancer incidence and geriatric adverse events.

2. Methods {#sec2-jcm-08-01550}
==========

2.1. Data Source {#sec2dot1-jcm-08-01550}
----------------

In this study, we used data from the Longitudinal Health Insurance Database 2000 (LHID2000), which is a subset of National Health Insurance research database (NHIRD.). LHID2000 contains the claims data of beneficiaries in the National Health Insurance (NHI) program of Taiwan, including details such as dates of inpatient and outpatient services, diagnoses, prescriptions, examinations, operations, and expenditures \[[@B14-jcm-08-01550]\]. LHID2000 includes the claims data of 1,000,000 individuals randomly sampled from all NHI enrollees (a total of 23.75 million people) in 2000. The demographic characteristics (i.e., age and sex) between the populations derived from the NHIRD and LHID2000 are comparable. This study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (Linkou Branch) (CMRP104-7810B).

2.2. Patient Identification and Definition of Exposure {#sec2dot2-jcm-08-01550}
------------------------------------------------------

We identified patients who had at least two outpatient diagnoses of BPH (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code: 600.xx) between 1 January, 1997 and 31 December, 2012. We first identified patients who received TURP between 1997 and 2012 by using the Taiwan NHI reimbursement codes of inpatient claims. The remaining patients who were prescribed alpha blockers for 90 days or longer within six months of the date of initial BPH diagnosis were classified as the medication-only group. For the TURP group, the index date was the discharge date following admission for TURP. For the medication-only group, the index date was the date of the initial prescription of alpha blockers for BPH.

Patients who met the following criteria were excluded: (1) age \< 50 years, (2) a diagnosis of prostate cancer or bladder cancer before the index date, (3) episodes of prostate cancer, bladder cancer, or all-cause mortality within six months post treatment, and (4) follow-up of \<6 months. Lastly, 6254 patients were included in the TURP group and 47,965 patients were included in the medication-only group.

The TURP and medication-only groups were further divided into two groups each, according to the presence or absence of adverse events (AEs) during the first six-month follow-up period. An AE was defined as follows: the occurrence of acute UR, urinary tract infection (UTI) with prescription of antibiotics, hematuria requiring endoscopic treatment, or bladder stone formation 31--180 days after the index date. Records of UTIs and bladder stone formation were extracted from the outpatient, emergency room, or inpatient claim data according to diagnostic codes (plus antibiotics) and Taiwan National Health Insurance (NHI) reimbursement codes, respectively. Urine retention (UR) was recorded only in outpatient and emergency room visits. The flow for patient selection is illustrated in [Figure 1](#jcm-08-01550-f001){ref-type="fig"}.

2.3. Covariates {#sec2dot3-jcm-08-01550}
---------------

The covariates were age, comorbidities, Charlson comorbidity index score \[[@B15-jcm-08-01550]\], tissue ablation, number of outpatient visits in the previous year, admission and AEs in the previous three years, use of statin or nonsteroidal anti-inflammatory drugs in the previous year, and use of overactive bladder drugs or alpha blockers. A comorbidity was defined as two outpatient diagnoses or one inpatient diagnosis in the previous year. Many diagnoses of these diseases in the NHIRD have been validated in relevant studies \[[@B16-jcm-08-01550]\]. The detailed International Classification of Disease, Ninth Modification (ICD-9-CM) diagnostic codes are listed in [Table 1](#jcm-08-01550-t001){ref-type="table"}. Medications were identified from the claim data of outpatient visits or records of pharmacy refills.

2.4. Outcome Detection {#sec2dot4-jcm-08-01550}
----------------------

Outcomes of primary interest were all-cause mortality, occurrence of prostate cancer, transurethral resection of the bladder tumor (TUR-BT), and radical cystectomy for treating bladder cancer. All-cause mortality was defined as withdrawal from the NHI program \[[@B17-jcm-08-01550]\]. The occurrence of prostate cancer was verified by the approval to possess a catastrophic illness certificate. Definitions of prostate cancer have been widely reported in NHIRD studies \[[@B18-jcm-08-01550]\]. TUR-BT and radical cystectomy operations were identified, according to the Taiwan NHI reimbursement codes of inpatient claim data. Secondary outcomes were long-term use of Benign Prostate Hypertrophy (BPH) medications (according to pharmacy refill records), recurrent adverse events (AEs)AEs, inguinal hernia, hemorrhoids, stroke, acute myocardial infarction, hip fracture, and spine fracture during the first three-year follow-up period. Each patient was followed from the index date to the date of event occurrence, date of death, or 31 December, 2012, whichever came first.

2.5. Statistics {#sec2dot5-jcm-08-01550}
---------------

To mitigate confounding factors due to treatment selection bias in this observational study, we adopted a propensity score matching method. The propensity score was the predicted probability of being in the AE group during the first 6-month follow-up, according to the values of covariates obtained using a logistic regression. [Table 2](#jcm-08-01550-t002){ref-type="table"} lists the variables selected to calculate the propensity score, where the follow-up year was replaced by the index date ([Table 2](#jcm-08-01550-t002){ref-type="table"}). Each patient in the AE group was matched with two corresponding patients in the non-AE group. The matching was processed using a greedy nearest neighbor algorithm with a caliper that was 0.2-times the value of the standard deviation of the logit of the propensity score by applying a random matching order without replacement. The quality of matching was assessed using the absolute value of the standardized difference (STD) between the groups, where a value \<0.1 was considered a negligible difference.

The difference in the risk of fatal outcomes (e.g., all-cause mortality) between the AE and non-AE groups was evaluated using the Cox proportional hazard model. The difference in incidence of nonfatal outcomes (e.g., Transurethral Resection of Bladder Tumor (TUR-BT)) between the groups was evaluated using the Fine and Gray sub-distribution hazard model, which considers all-cause mortality as a competing risk. The study group (AE compared with non-AE groups) was the only explanatory variable in the survival analyses. The within-pair clustering of outcomes after propensity score matching was accounted for by using a robust standard error, known as a marginal model \[[@B19-jcm-08-01550]\].

A two-sided *p* of \<0.05 was considered statistically significant, and no adjustment of multiple testing (multiplicity) was made in this study. All statistical analyses were performed using: Statistical Analysis System (SAS) (version 9.4, SAS Institute, Cary, NC, USA), including the procedures of "psmatch" for propensity score matching, "phreg" for survival analysis, and the macro "% cif" for generating a cumulative incidence function under the Fine and Gray sub-distribution hazard method.

3. Results {#sec3-jcm-08-01550}
==========

3.1. Study Population {#sec3dot1-jcm-08-01550}
---------------------

The data of 66,782 patients from the NHIRD were analyzed, as shown in [Figure 1](#jcm-08-01550-f001){ref-type="fig"}. Overall, 6254 patients who underwent TURP and 47,965 patients who underwent alpha blocker treatment were eligible for analysis. Both of the cohorts were further sub-grouped into an AE group and a non-AE group. After matching, we divided the included patients into the following four groups for analysis: TURP with AEs (*n* = 1108), TURP without AEs (*n* = 2216), alpha blockers with AEs (*n* = 2633), and alpha blockers without AEs (*n* = 5266). [Table 1](#jcm-08-01550-t001){ref-type="table"} and [Table 2](#jcm-08-01550-t002){ref-type="table"} list the basic characteristics of the patients who underwent TURP and medication only, respectively. No significant difference (STD absolute value \<0.1) was observed between the patients with AEs and those without AEs with respect to all of the covariates in either the TURP or medication-only groups.

3.2. Association between AEs and Treatment Outcomes {#sec3dot2-jcm-08-01550}
---------------------------------------------------

[Table 3](#jcm-08-01550-t003){ref-type="table"} details the relationship between the occurrence of post operation AEs and clinical outcomes during the follow-up period in the TURP group. Risk of all-cause mortality was comparable between the two groups (hazard ratio (HR): 1.07; 95% CI: 0.93--1.23), as shown in [Figure 2](#jcm-08-01550-f002){ref-type="fig"}A. However, patients who had an AE within six months following operation had a risk of bladder cancer formation requiring TUR-BT that was subsequently increased when compared with patients without AE (sub-distribution hazard ratio (SHR): 2.3; 95% CI: 1.56--3.39), as shown in [Figure 2](#jcm-08-01550-f002){ref-type="fig"}B. By contrast, the risk of prostate cancer formation remained similar between these groups (SHR: 1.20, 95% CI: 0.83--1.74). The risk of postop long-term medication dependence, both for alpha blockers and antimuscarinic medications, was also significantly different between the two groups, as indicated in [Figure 2](#jcm-08-01550-f002){ref-type="fig"}C. In addition, patients with post-operation AE had higher risk of long-term dependence on medications for LUTS, hemorrhoids, and hip fractures caused by accidental falls during the first three-year follow-up period.

[Table 4](#jcm-08-01550-t004){ref-type="table"} details the relationship between AEs following treatment with alpha blockers and clinical outcomes during the follow-up. Patients with AEs following alpha blocker treatment had a higher all-cause mortality rate (HR: 1.63, 95% CI: 1.49--1.78) compared with those without AEs, as indicated in [Figure 3](#jcm-08-01550-f003){ref-type="fig"}A. Patients with AEs following alpha blocker treatment also had a higher risk of bladder cancer formation requiring TUR-BT or radical cystectomy, as shown in [Figure 3](#jcm-08-01550-f003){ref-type="fig"}B,C. By contrast, the risk of prostate cancer formation remained similar (sub-distribution hazard ratio (SHR): 1.16, 95% CI: 0.84--1.61) between the two groups. In addition, patients with post-operation AEs had a higher risk of long-term dependence on medications for treating LUTS ([Table 5](#jcm-08-01550-t005){ref-type="table"}).

4. Discussion {#sec4-jcm-08-01550}
=============

UR, Urinary tract infection (UTI), gross hematuria with bladder tamponade, and bladder stone formation are all possible sequelae of benign prostate obstruction (BPO) and are regarded as absolute indications of TURP \[[@B20-jcm-08-01550]\]. However, it is frustrating for both physicians and patients if the previously mentioned complications reoccur despite treatment, regardless of whether the treatment is in the form of a surgical or medical intervention. According to the literature, unfavorable events of TURP include UTI (1.7--8.2%), UR (3--9%), hematuria with clot retention (2--5%), urethral strictures (2.2--9.8%), and bladder neck contractures (0.3--9.2%) \[[@B21-jcm-08-01550]\]. The incidence of unfavorable events following treatment with alpha blockers varies among reports \[[@B22-jcm-08-01550]\]. Nevertheless, no studies have focused on whether these unfavorable events affect older adults during long-term follow-up.

Before comparing the clinical outcomes of the four cohorts, 1:1 propensity score matching \[[@B23-jcm-08-01550]\] was performed to ensure that the characteristics of both groups were similar and that more objective data could be obtained. Therefore, as detailed in [Table 2](#jcm-08-01550-t002){ref-type="table"} and [Table 6](#jcm-08-01550-t006){ref-type="table"}, the distribution of parameters, including age, incidence of comorbidities, and Charlson comorbidity index, did not differ significantly between each two groups. The major finding of this research is that post-treatment AEs (whether following surgical or medical intervention) are significantly correlated with bladder cancer formation during lifelong follow-up. Bladder cancer is the ninth most common cancer worldwide, with an estimated 430,000 new cases in 2012 \[[@B24-jcm-08-01550]\]. Bladder cancer resulted in 170,000 deaths globally in 2011, which demonstrates an increase from the 114,000 deaths in 1990 of 19.4% after adjusting for the increase in the total world population \[[@B25-jcm-08-01550]\]. Data collected using the Taiwan Cancer Registry database suggest that the incidence of bladder cancer in the general population is approximately 0.21% \[[@B26-jcm-08-01550]\]. However, the patients included in our study exhibited a higher bladder cancer incidence compared with the Taiwan general population. Patients with post-treatment AE even had a greater risk of bladder cancer than those without AE. This phenomenon indicates that an unfavorable treatment outcome for BPO is associated with an increased incidence of bladder cancer.

Multiple factors are associated with bladder cancer development. However, smoking tobacco is the main known contributor \[[@B27-jcm-08-01550]\]. The number of cigarettes smoked, degree of inhalation, type of tobacco, use of filters, and smoking cessation all have significant relationships with bladder cancer development \[[@B28-jcm-08-01550]\]. In addition, common candidate genes or pathways, such as carcinogenic metabolizing genes, DNA repair genes, apoptosis-related genes, and microRNA-related genes, have been studied widely and can contribute to the risk of bladder cancer \[[@B29-jcm-08-01550]\]. Clinically, men with severe LUTS have a 64% higher relative risk of bladder cancer compared with men who report no LUTS. A recent study even revealed that patients with BPH who underwent TURP were at a higher risk of bladder cancer (HR = 6.17, 95%, CI = 3.68--10.3) than those who did not \[[@B30-jcm-08-01550]\]. The sequelae of unfavorable BPO treatment outcomes, such as high post-voiding residual urine volume, repeat UTIs, chronic bladder inflammation, and chronic UR, all increase urothelial exposure to carcinogens and, thus, increase the risk of bladder cancer \[[@B31-jcm-08-01550]\]. After chronic inflammation develops, it can mediate cancer pathogenesis by stimulating malignant cell growth, invasion, and metastasis through the recruitment of inflammatory cells and signaling molecules \[[@B32-jcm-08-01550]\]. Therefore, an unfavorable treatment outcome for BPO is associated with an increasing bladder cancer incidence.

Similar to bladder cancer development, that of prostate cancer is positively associated with chronic tissue inflammation and bacterial infection \[[@B33-jcm-08-01550]\]. Another study also reported that chronic tissue inflammation is associated with an increased risk of both prostate and bladder cancer, and a subgroup analysis by ethnicity suggested that the association was much stronger in Asian patients than in Caucasian patients \[[@B34-jcm-08-01550]\]. A study pertaining to microbiomes indicated a prevalence of pro-inflammatory bacteria and uro-pathogens in the urinary tract of men with prostate cancer \[[@B35-jcm-08-01550]\]. Urinary microbiomes influence chronic inflammation in the prostate and lead to prostate cancer development and progression \[[@B35-jcm-08-01550]\]. Nevertheless, the findings of our study suggest that an unfavorable treatment outcome for BPO is not associated with prostate cancer development. Our explanation for this phenomenon is that prostate cancer development is mediated in part by chronic inflammation as well as by genetics and exposure to toxins in the environment. Thus, compared with unfavorable BPO treatment outcomes, other factors such as age, race, family medical history, lifestyle, and presence of metabolic syndrome might be stronger contributors to prostate cancer development.

Another notable finding of this study is that the treatment outcome of BPO had a substantial impact on the health status of male patients. In the medication-only group, patients with AEs, despite regular alpha blocker treatment, had a higher risk of all-cause mortality. By contrast, patients with AE following TURP also had increased risk of hemorrhoids, hip fracture caused by accidental falls, and medication dependence (alpha blockers or antimuscarinic medications) during a three-year follow-up. Many patients have persistent voiding dysfunction after surgical treatment for BPO. Older age, history of diabetes, history of cerebrovascular accidents, and preoperative antimuscarinic drug use are possible risk factors of continuing medical therapy following TURP \[[@B36-jcm-08-01550]\]. We used 1:1 propensity score matching to eliminate the influence of the previously mentioned factors and concluded that the occurrence of AE within the six months following operation is also strongly associated with lifelong dependence on urologic medications.

This study has some limitations as a result of the NHIRD data structure. First, this database does not provide detailed personal information such as family cancer history, laboratory parameters, cigarette use, environmental toxin exposure, body mass index (BMI), and dietary habits, which are all confounding variables that influence prostate and bladder cancer development. Second, we used a strict criterion to divide our study population into two categories: patients with or without AEs. Thus, we could not assess how the duration, frequency, and severity of AEs affected treatment outcomes. Third, the use of laser prostatic vaporization or vapor-resection, which is not reimbursed by the Taiwan NHI, has only become increasingly common in the last decade \[[@B37-jcm-08-01550]\]. Thus, patients receiving prostate laser treatment were not included in this database. However, despite these limitations, we believe that this is innovative and valid research. This study confirmed that unfavorable treatment outcomes of BPH increase the incidence of bladder cancer and have negative health effects among older men.

5. Conclusions {#sec5-jcm-08-01550}
==============

This nationwide database study reveals that unfavorable outcomes of BPH following either medication-based or surgical treatment are associated with a higher bladder cancer incidence. These outcomes, subsequently, lead to negative health effects in older men.
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###### 

Unadjusted cumulative event rate of all-cause mortality (**A**), cumulative incidence of transurethral resection of the bladder tumor (**B**), and long-term use of medications for treating benign prostatic hyperplasia (**C**) in patients with and without adverse events during the first six-month follow-up in the TURP cohort.
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![Unadjusted cumulative event rate of all-cause mortality (**A**), cumulative incidence of transurethral resection of bladder tumor (**B**), and cumulative incidence of radical cystectomy (**C**) in patients with and without adverse events during the first six-month follow-up in the medication-only cohort.](jcm-08-01550-g003){#jcm-08-01550-f003}

jcm-08-01550-t001_Table 1

###### 

ICD-9-CM codes used in the current study.

  Variable                                Code
  --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Benign prostatic hyperplasia            600.xx, A360
  Prostate cancer                         185.xx (Catastrophic illness certificate)
  Bladder cancer                          188.9x (Catastrophic illness certificate)
  Diabetes mellitus                       250.xx
  Hypertension                            401.xx--405.xx
  Hyperlipidemia                          272.xx
  Chronic obstructive pulmonary disease   491.xx, 492.xx, 496.xx
  Parkinsonism                            332.xx
  Chronic kidney disease                  580.xx--589.xx, 403.xx--404.xx, 016.0x, 095.4x, 236.9x, 250.4x, 274.1x, 442.1x, 447.3x, 440.1x, 572.4x, 642.1x, 646.2x, 753.1x, 283.11, 403.01, 404.02, 446.21
  Ischemic heart disease                  410.xx--414.xx
  Stroke                                  430.xx--434.xx
  Heart failure                           428.xx
  Alcoholism                              V113, 291.xx, 305.0x, 357.5, 425.5, 303.xx, 571.0, 571.1, 571.2, 571.3, 980.0
  Drug abuse                              303.xx--305.xx
  Urinary tract infection                 599.0x, 595.0x
  Hemorrhoids                             455.xx
  Acute myocardial infarction             410.xx
  Hip fracture                            820.xx
  Spine fracture                          805.xx, 806.xx

ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.

jcm-08-01550-t002_Table 2

###### 

Baseline characteristics of patients with BPH who received TURP grouped according to the presence or absence of AEs during the six-month follow-up period.

  Variable                                         Before Matching   After Matching                                            
  ------------------------------------------------ ----------------- ---------------- -------- --------------- --------------- --------
  Age (years)                                      72.9 ± 8.0        71.6 ± 8.0       0.160    72.7 ± 8.0      72.5 ± 7.8      0.021
  Comorbidity                                                                                                                  
  Diabetes mellitus                                227 (19.0)        867 (17.1)       0.049    203 (18.3)      413 (18.6)      −0.008
  Hypertension                                     596 (49.9)        2106 (41.6)      0.167    534 (48.2)      1075 (48.5)     −0.006
  Hyperlipidemia                                   142 (11.9)        450 (8.9)        0.098    124 (11.2)      244 (11.0)      0.006
  Chronic obstructive pulmonary disease            229 (19.2)        657 (13.0)       0.169    191 (17.2)      361 (16.3)      0.025
  Parkinsonism                                     34 (2.8)          93 (1.8)         0.067    24 (2.2)        51 (2.3)        −0.009
  Chronic kidney disease                           124 (10.4)        483 (9.5)        0.028    117 (10.6)      221 (10.0)      0.019
  Ischemic heart disease                           236 (19.8)        791 (15.6)       0.108    196 (17.7)      405 (18.3)      −0.015
  Stroke                                           165 (13.8)        408 (8.1)        0.185    123 (11.1)      252 (11.4)      −0.009
  Heart failure                                    54 (4.5)          166 (3.3)        0.064    41 (3.7)        92 (4.2)        −0.023
  Alcoholism                                       6 (0.5)           10 (0.2)         0.052    1 (0.09)        5 (0.23)        −0.034
  Drug abuse                                       3 (0.3)           13 (0.3)         −0.001   1 (0.09)        4 (0.18)        −0.025
  CCI score                                        1.5 ± 1.7         1.2 ± 1.5        0.218    1.4 ± 1.6       1.4 ± 1.7       0.002
  Tissue ablation                                                                                                              
  5--15 g                                          850 (71.2)        3771 (74.5)      −0.075   791 (71.4)      1576 (71.1)     0.006
  15--50 g                                         288 (24.1)        1086 (21.5)      0.063    269 (24.3)      538 (24.3)      0.000
  \>50 g                                           56 (4.7)          203 (4.0)        0.033    48 (4.3)        102 (4.6)       −0.013
  Urologic event in the previous three years                                                                                   
  Urinary tract infection                          484 (40.5)        1192 (23.6)      0.370    401 (36.2)      790 (35.6)      0.011
  Urinary retention                                495 (41.5)        1783 (35.2)      0.128    445 (40.2)      898 (40.5)      −0.007
  Bladder stone                                    39 (3.3)          137 (2.7)        0.033    34 (3.1)        67 (3.0)        0.003
  Urologic drug use in the previous three months                                                                               
  Anti-muscarinic                                  114 (9.5)         488 (9.6)        −0.003   108 (9.7)       221 (10.0)      −0.008
  Alpha-blockers                                   920 (77.1)        3817 (75.4)      0.038    851 (76.8)      1706 (77.0)     −0.004
  Propensity score                                 0.235 ± 0.105     0.181 ± 0.085    0.569    0.216 ± 0.082   0.215 ± 0.081   0.008
  Follow-up years                                  6.3 ± 3.8         7.3 ± 4.3        −0.225   6.5 ± 3.9       6.7 ± 3.9       −0.050

STD, standardized difference. BPH, benign prostatic hyperplasia. TURP, transurethral resection of the prostate. AE, adverse event. CCI, Charlson comorbidity index.

jcm-08-01550-t003_Table 3

###### 

Treatment outcomes during follow-up of patients with BPH who underwent TURP.

  Variable                                            AE (*n* = 1108)   Non-AE (*n* = 2216)   AE vs. Non-AE       
  --------------------------------------------------- ----------------- --------------------- ------------------- ---------
  **Primary Outcome at the End of Follow Up**                                                                     
  All-cause mortality                                 431 (38.9)        827 (37.3)            1.07 (0.93, 1.23)   0.332
  Prostate cancer                                     31 (2.8)          56 (2.5)              1.20 (0.83, 1.74)   0.337
  TUR-BT                                              36 (3.2)          32 (1.4)              2.30 (1.56, 3.39)   \<0.001
  Radical cystectomy                                  5 (0.5)           1 (0.0)               NA                  NA
  **Secondary outcome during three-year follow-up**                                                               
  Medication dependence                                                                                           
  Anti-muscarinic                                     30 (2.7)          26 (1.2)              2.27 (1.48, 3.46)   \<0.001
  Alpha-blocker                                       112 (10.1)        172 (7.8)             1.31 (1.08, 1.59)   0.006
  Inguinal hernia                                     40 (3.6)          59 (2.7)              1.35 (0.98, 1.87)   0.066
  Hemorrhoids                                         132 (11.9)        195 (8.8)             1.39 (1.16, 1.66)   \<0.001
  Stroke                                              56 (5.1)          118 (5.3)             0.97 (0.74, 1.25)   0.788
  AMI                                                 8 (0.7)           19 (0.9)              0.80 (0.40, 1.57)   0.511
  Hip fracture                                        21 (1.9)          20 (0.9)              2.26 (1.37, 3.71)   0.001

TURP, transurethral resection of the prostate. AE, adverse event. HR, hazard ratio. SHR, sub-distribution hazard ratio. CI, confidence interval. TUR-BT, transurethral resection of bladder tumor. NA, not applicable. AMI: Acute myocardial infarction.

jcm-08-01550-t004_Table 4

###### 

Treatment outcomes during follow-up of patients with BPH who received alpha blocker therapy.

  Variable                                            AE (*n* = 2633)   Non-AE (*n* = 5266)   AE vs. Non-AE        
  --------------------------------------------------- ----------------- --------------------- -------------------- ---------
  **Primary Outcome at the End of Follow Up**                                                                      
  All-cause mortality                                 1272 (48.3)       2060 (39.1)           1.63 (1.49, 1.78)    \<0.001
  Prostate cancer                                     44 (1.7)          89 (1.7)              1.16 (0.84, 1.61)    0.354
  TUR-BT                                              66 (2.5)          49 (0.9)              2.72 (1.99, 3.71)    \<0.001
  Radical cystectomy                                  15 (0.6)          3 (0.1)               7.68 (2.54, 23.28)   \<0.001
  **Secondary outcome during three-year follow-up**                                                                
  Inguinal hernia                                     55 (2.1)          96 (1.8)              1.12 (0.85, 1.47)    0.418
  Hemorrhoids                                         202 (7.7)         403 (7.7)             1.04 (0.90, 1.19)    0.629
  Stroke                                              143 (5.4)         262 (5.0)             1.06 (0.90, 1.26)    0.475
  AMI                                                 30 (1.1)          45 (0.9)              1.33 (0.91, 1.92)    0.137
  Hip fracture                                        36 (1.4)          82 (1.6)              0.93 (0.67, 1.29)    0.651

AE, adverse event. HR, hazard ratio. SHR, sub-distribution hazard ratio. CI, confidence interval. TUR-BT, transurethral resection of the bladder tumor. AMI, acute myocardial infarction.

jcm-08-01550-t005_Table 5

###### 

Association between baseline characteristics and long-term use of medications for treating BPH among patients with BPH who received TURP (*n* = 6254).

  Predictor                                             HR     95% CI       *p* Value
  ----------------------------------------------------- ------ ------------ -----------
  Age ≥ 75 years                                        1.29   1.07--1.56   0.008
  BPH duration (years)                                  1.13   1.10--1.16   \<0.001
  Adverse event during the six-month follow up          1.45   1.18--1.79   \<0.001
  Hypertension                                          1.82   1.49--2.22   \<0.001
  Hyperlipidemia                                        1.51   1.17--1.94   0.002
  Urinary tract infection in the previous three years   1.23   1.01--1.49   0.039
  NSAIDs use in the previous year                       1.35   1.11--1.63   0.002
  Alpha-blocker use in the previous three months        1.61   1.21--2.14   0.001

BPH, benign prostatic hyperplasia. TURP, transurethral resection of the prostate. HR, hazard ratio. CI, confidence interval. NSAIDs, nonsteroidal anti-inflammatory drugs.

jcm-08-01550-t006_Table 6

###### 

Baseline characteristics of patients with BPH who received alpha blocker therapy grouped according to the presence or absence of AEs during the six-month follow-up period.

                                                   Before Matching   After Matching                                            
  ------------------------------------------------ ----------------- ---------------- -------- --------------- --------------- --------
  Age (years)                                      70.1 ± 10.3       66.7 ± 9.9       0.335    69.8 ± 10.3     70.1 ± 10.8     −0.023
  Comorbidity                                                                                                                  
  Diabetes mellitus                                641 (23.4)        7414 (16.4)      0.175    589 (22.4)      1193 (22.7)     −0.007
  Hypertension                                     1264 (46.1)       17292 (38.2)     0.159    1192 (45.3)     2424 (46.0)     −0.015
  Hyperlipidemia                                   309 (11.3)        5598 (12.4)      −0.035   300 (11.4)      604 (11.5)      −0.002
  Chronic obstructive pulmonary disease            466 (17.0)        4752 (10.5)      0.189    412 (15.6)      853 (16.2)      −0.015
  Parkinsonism                                     85 (3.1)          539 (1.2)        0.132    75 (2.8)        155 (2.9)       −0.006
  Chronic kidney disease                           324 (11.8)        3010 (6.7)       0.179    296 (11.2)      603 (11.5)      −0.007
  Ischemic heart disease                           484 (17.6)        5985 (13.2)      0.122    450 (17.1)      936 (17.8)      −0.018
  Stroke                                           533 (19.4)        3580 (7.9)       0.340    460 (17.5)      934 (17.7)      −0.007
  Heart failure                                    173 (6.3)         1067 (2.4)       0.195    143 (5.4)       312 (5.9)       −0.021
  Alcoholism                                       33 (1.2)          347 (0.8)        0.044    32 (1.22)       74 (1.41)       −0.017
  Drug abuse                                       19 (0.7)          238 (0.5)        0.021    19 (0.72)       40 (0.76)       −0.004
  CCI score                                        1.6 ± 1.9         1.0 ± 1.5        0.385    1.5 ± 1.8       1.6 ± 1.9       −0.021
  Urology event in the previous three years                                                                                    
  Urinary tract infection                          893 (32.6)        4408 (9.7)       0.582    783 (29.7)      1541 (29.3)     0.010
  Urinary retention                                529 (19.3)        1693 (3.7)       0.502    419 (15.9)      780 (14.8)      0.031
  Bladder stone                                    39 (1.4)          223 (0.5)        0.095    32 (1.2)        52 (1.0)        0.022
  Urologic drug use in the previous three months                                                                               
  Anti-muscarinic                                  79 (2.9)          675 (1.5)        0.095    74 (2.8)        162 (3.1)       −0.016
  Alpha-blockers                                   ---               ---              ---      ---             ---             ---
  Propensity score                                 0.121 ± 0.126     0.053 ± 0.053    0.705    0.105 ± 0.096   0.104 ± 0.095   0.003
  Follow-up years                                  5.1 ± 3.8         6.7 ± 4.3        −0.404   5.1 ± 3.8       5.9 ± 3.9       −0.200

STD, standardized difference. AE, adverse event. CCI, Charlson comorbidity index.

[^1]: These authors contribute equally to this paper.
